LXRαにおけるアラニン-327のLXRβ型ヒスティジンへの変異は,リカルディンCによるその亜型選択的活性化を悪化させる
Norimasa Tamehiro1, Yukari Shigemoto-Mogami2, Hongyan Cui1
1Division of Biochemistry, National Institute of Health Sciences, Tonomachi 3-25-26, Kawasaki-ku, Kanagawa 210-9501, Japan.
Biochemical pharmacology
|September 4, 2025
まとめ
リッカルディンCは特定の変異を標的として肝臓X受容体α (LXRα) を選択的に活性化し,肝臓脂肪の増加などの副作用のない脂質障害に対する潜在的な治療戦略を提供します.
科学分野:
- 分子内分泌学
- 脂質代謝
- 薬物の発見
背景:
- 肝臓X受容体 (LXRαとLXRβ) は,脂質安定と炎症の主要な調節体である.
- 現在使用されているLXRアゴニストは,肝臓の脂質生成に有害な作用があるため,限界に直面しています.
- リッカルディンC (RC) は選択的LXRα部分的アゴニズムとLXRβアンタゴニズムを示す.
研究 の 目的:
- 肝臓X受容体α (LXRα) のリッカリンC (RC) 誘発による選択的活性化の原因となる分子機構を解明する.
- LXRサブタイプにおけるRCの差分活性に重要な特定のドメインとアミノ酸残基を特定する.
- 脂質障害の管理のためのRCの治療の可能性を in vivoで評価する.
主な方法:
- LXRα/βキメラと点変異受容体の生成と機能分析
- コアクティベーターペプチド結合とトランザクティベーションの評価
- 遺伝子発現,脂質プロファイル,HDLレベルに対するRCの影響を評価するためにマウスでのin vivo研究.
主要な成果:
- LXRαヘリックス6における特定の変異 (アラニン327からヒスティジン) は,RC誘発の活性化と共活性化因子の相互作用において決定的であることが確認された.
- LXRβまたは不活性なキメラにおけるLXRαを模倣する変異は,部分的にRC応答性を回復させた.
- 肝臓と腸のAbca1を選択的に上昇させ,トリグリセリドを増加させずにHDLを上昇させた.
結論:
- LXRαにおけるA327H変異は,Riccardin Cによる選択的活性化の重要な決定因子である.
- 肝臓の脂質生成を促進することなく,HDLレベルを高めることで,血脂不全の治療薬としての可能性を示しています.
- これらの発見は,動脈硬化症および関連する炎症性疾患の標的型LXRベースの治療法の開発に道を開きます.
さらに関連する動画
09:07Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation
Published on: June 21, 2016
8.3K
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
6.4K
関連する概念動画
00:49Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
01:31Adrenergic Receptors: ɑ Subtype
1.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.7K
01:29The Two-State Receptor Model
2.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.4K
01:08Allosteric Regulation
59.0K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
59.0K
01:26Adrenergic Receptors: β Subtype
2.0K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.0K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K